Collaborating with Ametris on data-driven research for MND sufferers
At AIBN we know how important robust data is for advancing treatments for devastating diseases.
In 2026, AIBN's Associate Professor Shyuan Ngo - or Shu as she is known - will launch a phase 2B clinical trial to test whether Trimetazidine - a commonly used heart medication - can improve metabolism, function, and quality of life for people with amyotrophic lateral sclerosis (ALS), the most common form of MND.
Tracking the progression of MND and the effectiveness of potential treatments usually involves participants traveling to clinics and self-reporting their activity and experiences. While these methods are considered the global standard for MND clinical trials, Shu believes there could be a more participant-friendly approach.
Enter the Ametris Actigraph LEAP smartwatch. This device continuously monitors key health and activity metrics, including movement patterns, heart rate, and sleep quality. Capturing these metrics during a patient’s daily routine provides invaluable insights for researchers and enhances the depth of clinical trial data.
Together, we can bring closer a future free from MND
As part of UQ's Giving Day this year, we are raising funds to support the purchase of these smartwatches to be worn by MND Warriors in the comfort of their own homes, capturing real-time insights for the upcoming clinical trial of a promising new therapy.